Scientists have identified a brief period immediately after brain tumor surgery when the brain’s natural defenses temporarily drop, opening a potential new window to deliver chemotherapy directly to remaining cancer cells. The early-stage finding, published in the journal Science Translational Medicine, could reshape standard care for glioblastoma, the deadliest form of brain cancer.
Currently, patients typically wait four to six weeks after surgery before starting chemotherapy and radiotherapy, a delay meant to allow recovery. But researchers at The University of Manchester found that the blood-brain barrier, a protective layer that normally blocks most drugs from reaching the brain, becomes temporarily disrupted in two distinct phases shortly after tumor removal. In mouse studies that mimicked human surgery, the team showed that delivering treatment during these windows significantly suppressed tumor recurrence.
“For the first time, we’ve shown that glioblastoma surgery briefly exposes a vulnerability we can exploit,” said Dr. Thomas Kisby, co-lead author of the study. “If treatment is timed during specific windows we identified, it is able to halt the disease significantly before it regrows.” The researchers suggest the hours and days immediately after surgery may hold the key to stopping the cancer from returning, and that existing medicines could be redeployed more strategically.
Glioblastoma affects about 3,200 people annually in the UK, and only around 160 survive five years or more. The tumors grow rapidly and penetrate multiple brain regions, causing symptoms such as headaches, personality changes, memory problems, speech difficulties, and extreme fatigue. Standard treatment currently involves surgery followed by chemotherapy and radiotherapy, but recurrence is nearly universal.
Co-lead author Professor Kostas Kostarelos, from The University of Manchester and the Catalan Institute of Nanoscience and Nanotechnology, said the research “has the potential to open a new frontier in post-operative cancer care.” He noted that brain tumors often regrow from tissue surrounding the surgical site, and proposed using targeted treatments, including nanoparticle-based medicines, immunotherapy, and gene therapies, during the vulnerable window to improve long-term survival odds.
Dr. Gerben Borst, honorary consultant oncologist at The Christie NHS Foundation Trust, said the findings offer a practical path forward. “One of the greatest challenges in treating glioblastoma is eliminating the microscopic cancer cells that remain after surgery,” he said. “These findings suggest that a better understanding of the body’s natural response to surgery could help us deliver anti-cancer drugs more effectively, rather than relying solely on the development of entirely new and costly medicines.”
Experts caution that the results are still preliminary and based on laboratory models. Clinical trials are needed to confirm whether the approach benefits human patients. Dr. Simon Newman, chief scientific officer at The Brain Tumour Charity, called the study “vital” and said the next step is translating the laboratory findings into patient studies. The charity also supports an ongoing clinical study assessing which drugs can cross the blood-brain barrier in patients.
The research arrives amid growing public pressure for better brain cancer care. Archie Goodburn, a 25-year-old Scottish swimmer diagnosed with brain cancer at 22, recently made an emotional plea for a national brain cancer lead, saying trials available worldwide are not reaching UK patients. Prime Minister Andy Burnham has invited Goodburn to meet. For now, the Manchester team’s discovery offers a hopeful new direction: using the body’s own response to surgery as a tool to fight back, potentially improving survival for one of the most challenging cancers in medicine.